Danaher (NYSE:DHR) Price Target Raised to $230.00 at Wells Fargo & Company

Key Points

• Wells Fargo & Company has raised its price target for Danaher from $205.00 to $230.00, indicating a potential upside of 5.49% from the current stock price.
• Danaher recently reported earnings of $1.89 per share, exceeding analysts' expectations, with revenue of $6.05 billion for the quarter.
• Eighteen analysts have rated Danaher as a Buy with a consensus price target of $248.92, reflecting strong market confidence in the company's performance.

Danaher (NYSE:DHR - Get Free Report) had its price target upped by equities researchers at Wells Fargo & Company from $205.00 to $230.00 in a research note issued on Wednesday,MarketScreener reports. The firm presently has an "equal weight" rating on the conglomerate's stock. Wells Fargo & Company's target price indicates a potential upside of 5.49% from the company's current price.

Several other research analysts have also recently weighed in on the company. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective on the stock in a research report on Friday, July 11th. TD Cowen raised their price target on shares of Danaher from $250.00 to $260.00 and gave the company a "buy" rating in a research report on Wednesday. Rothschild & Co Redburn reaffirmed a "neutral" rating and set a $220.00 price target (down previously from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Guggenheim reiterated a "buy" rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Finally, Evercore ISI lifted their price objective on Danaher from $226.00 to $245.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. Eighteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $248.92.

Danaher Price Performance

DHR traded down $2.74 on Wednesday, reaching $218.03. The company had a trading volume of 560,296 shares, compared to its average volume of 4,235,630. Danaher has a one year low of $171.00 and a one year high of $260.88. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company has a fifty day moving average of $202.07 and a 200-day moving average of $197.59. The company has a market capitalization of $156.12 billion, a P/E ratio of 46.39, a PEG ratio of 3.01 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.71 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts anticipate that Danaher will post 7.63 earnings per share for the current year.

Insider Activity at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 11.20% of the company's stock.

Institutional Trading of Danaher

Several large investors have recently modified their holdings of the business. Norges Bank acquired a new position in shares of Danaher in the 2nd quarter valued at $1,979,503,000. Nuveen LLC acquired a new stake in shares of Danaher in the first quarter valued at approximately $833,941,000. Viking Global Investors LP increased its stake in shares of Danaher by 543.9% during the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate's stock valued at $574,351,000 after acquiring an additional 2,455,994 shares during the period. Generation Investment Management LLP boosted its holdings in Danaher by 56.2% during the second quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate's stock worth $980,914,000 after buying an additional 1,787,522 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.